No Detail Found!

Preparation and in vitro/in vivo evaluation of a pantoprazole sodium drug-resin liquid delayed release suspension

Author(s)
Xinyi Tang College of Pharmacy, Anhui University of Chinese Medicine, Hefei, PR China; Yangtze Delta Drug Advanced Research Institute, Nantong, PR China; Jiangsu Haizhihong Biopharmaceutical Co., Ltd, Nantong, PR China
Xianghuan Meng Jiangsu University,Zhenjiang,PR China
Ke Li Yangtze Delta Drug Advanced Research Institute, Nantong, PR China; Jiangsu Haizhihong Biopharmaceutical Co., Ltd, Nantong, PR China
Zhannuan Yin College of Pharmacy, Anhui University of Chinese Medicine, Hefei, PR China; Yangtze Delta Drug Advanced Research Institute, Nantong, PR China; Jiangsu Haizhihong Biopharmaceutical Co., Ltd, Nantong, PR China
Haibing He Jiangsu Haizhihong Biopharmaceutical Co., Ltd, Nantong, PR China; Department of Pharmaceutics, Shen yang Pharmaceutical University, Shen yang, PR China
Hongfei Liu College of Pharmacy, Anhui University of Chinese Medicine, Hefei, PR China; Yangtze Delta Drug Advanced Research Institute, Nantong, PR China; Jiangsu University, Zhenjiang, PR China; Jiangsu Haizhihong Biopharmaceutical Co., Ltd, Nantong, PR China
Abstract
A drug-resin liquid delayed-release suspension of pantoprazole sodium (PAZ-Na) was prepared to improve the effectiveness, convenience and safety of peptic ulcer treatment in children, the elderly, and patients with dysphagia. Pantoprazole sodium drug-resin complexes (PAZ-Na-DRC) were prepared using the bath method. The fluidized bed coating method is used to coat it and then add excipients to make a dry suspension prepared before use. The parameters of the in vitro release experimental conditions were optimized and the drug release curve showed delayed release. Rats were given commercial PAZ-Na enteric-coated pellet capsules and the PAZ-Na delayed release suspension via intragastric administration. The results showed that the Tmax of the PAZ-Na delayed release suspension was increased from 2h to 4h compared with the PAZ-Na enteric-coated pellet capsules. Similarly, the Cmax was reduced from 6.162µg/mL to 3.244µg/mL with the concentration-time curve is very gentle compared with the commercial drug capsules. After oral administration, the relative bioavailability of PAZ-Na delayed release suspension (AUC0-24 of 19.578 µg·h·mL-1) compared with the commercial drug (AUC0-24 of 17.388 µg·h·mL-1) was 112.67%. The findings showed that the PAZ-Na delayed release suspension for oral administration was successfully formulated with highly improved pharmacokinetic indices.
Publication Details
Page(s) 385-397
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 37, Issue: 2, Year: 2024

Request the full text from PASTIC

Keywords
Anion exchange resin, delayed release suspension, pantoprazole sodium
0

Citations

0

Downloads

79

Views